Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,225,748
  • Shares Outstanding, K 184,447
  • Annual Sales, $ 13,453 M
  • Annual Income, $ 4,431 M
  • 60-Month Beta 1.02
  • Price/Sales 3.02
  • Price/Cash Flow 6.93
  • Price/Book 3.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 8.28
  • Number of Estimates 25
  • High Estimate 9.15
  • Low Estimate 7.80
  • Prior Year 7.40
  • Growth Rate Est. (year over year) +11.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
219.70 +29.21%
on 10/03/19
318.00 -10.73%
on 10/22/19
+45.08 (+18.88%)
since 09/20/19
3-Month
215.77 +31.56%
on 09/04/19
318.00 -10.73%
on 10/22/19
+51.39 (+22.11%)
since 07/22/19
52-Week
215.77 +31.56%
on 09/04/19
344.00 -17.48%
on 01/23/19
-31.67 (-10.04%)
since 10/22/18

Most Recent Stories

More News
Earnings Data Deluge

Earnings Data Deluge

BIIB : 283.60 (+26.88%)
MCD : 201.36 (-4.05%)
UAA : 21.06 (+4.83%)
Company says it will seek approval of Alzheimer's drug

The drug company Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most...

BIIB : 283.60 (+26.88%)
Biogen (BIIB) Up 40% on Alzheimer's Drug & More

This is about as "game changer" as a drug can get, at least in the early stages.

BIIB : 283.60 (+26.88%)
MCD : 201.36 (-4.05%)
UAA : 21.06 (+4.83%)
Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab

Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.

RHHBY : 36.4900 (-0.65%)
ABBV : 78.19 (+1.15%)
JNJ : 130.04 (+1.58%)
BIIB : 283.60 (+26.88%)
Biogen (BIIB) Q3 Earnings & Sales Beat Estimates

Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.

BIIB : 283.60 (+26.88%)
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer's disease as measured by the pre-specified primary and secondary endpoints

BIIB : 283.60 (+26.88%)
Earnings Surprise May Lift Stocks: Buy These Growth ETFs

Market participants are betting on the record-high U.S. indices as about 120 S&P 500 companies are scheduled to release their results this week.

EBAY : 39.15 (-0.28%)
VZ : 60.95 (+0.33%)
NOC : 353.00 (+0.74%)
CMCSA : 45.86 (-0.48%)
MSFT : 137.93 (-0.36%)
VUG : 168.10 (-0.41%)
MGK : 133.81 (-0.30%)
IWY : 88.41 (-0.18%)
IWF : 161.62 (-0.25%)
SPYG : 39.01 (-0.28%)
QQQ : 192.96 (-0.22%)
BIIB : 283.60 (+26.88%)
CMG : 834.95 (-1.95%)
PG : 123.66 (+3.85%)
HAS : 101.13 (-15.84%)
Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week

Biogen Inc. (Nasdaq: BIIB) and Samsung Bioepis today announced that they will present new real-world data from the companies' anti-TNF biosimilar portfolio, which includes FLIXABI(TM) (infliximab) and...

BIIB : 283.60 (+26.88%)
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth

RHHBY : 36.4900 (-0.65%)
GILD : 66.01 (+1.23%)
AMGN : 204.46 (+0.75%)
BIIB : 283.60 (+26.88%)
Biogen Strengthens MS & SMA Portfolio as Competition Lurks

Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon...

RHHBY : 36.4900 (-0.65%)
NVS : 87.01 (+0.52%)
ALKS : 18.69 (+1.52%)
BIIB : 283.60 (+26.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 227.84
1st Resistance Point 225.67
Last Price 282.01
1st Support Level 221.45
2nd Support Level 219.40

See More

52-Week High 344.00
Fibonacci 61.8% 295.02
Last Price 282.01
Fibonacci 50% 279.89
Fibonacci 38.2% 264.76
52-Week Low 215.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar